DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
AV-101 is an investigational drug.
There have been 5 clinical trials for AV-101. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2021.
The most common disease conditions in clinical trials are Dyskinesia, Drug-Induced, Depressive Disorder, Major, and Pulmonary Arterial Hypertension. The leading clinical trial sponsors are VistaGen Therapeutics, Inc., Michael Debakey Veterans Affairs Medical Center, and Michael E. DeBakey VA Medical Center.
There are twenty-six US patents protecting this investigational drug and two hundred and sixty-five international patents.
Recent Clinical Trials for AV-101
|AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia||VistaGen Therapeutics, Inc.||Phase 2|
|A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)||Aerovate Therapeutics||Phase 2/Phase 3|
|Electrophysiological Biomarkers of AV-101||Michael Debakey Veterans Affairs Medical Center||Phase 1/Phase 2|
Top disease conditions for AV-101
Top clinical trial sponsors for AV-101
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|AV-101||⤷ Try it Free||Controlled release dosage form||TRIASTEK, INC. (Nanjing, CN)||⤷ Try it Free|
|AV-101||⤷ Try it Free||Oral drug dosage forms having desired drug release profiles and uses thereof||Triastek, Inc. (Nanjing, CN)||⤷ Try it Free|
|AV-101||⤷ Try it Free||Methods for the synthesis of chiral kynurenine compounds||VISTAGEN THERAPEUTICS, INC. (South San Francisco, CA)||⤷ Try it Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|AV-101||Australia||AU2017261372||2036-05-05||⤷ Try it Free|
|AV-101||Canada||CA3023278||2036-05-05||⤷ Try it Free|
|AV-101||China||CN107847398||2036-05-05||⤷ Try it Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|